In the current review, we discuss the current evidence on the use of SGLT2 inhibitors in special populations, including patients with acute myocardial infarction (AMI), acute HF, right ventricular (RV) failure, with left ventricular assist device (LVAD), and with type 1 diabetes. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.